PMID- 35993417
OWN - NLM
STAT- MEDLINE
DCOM- 20221024
LR  - 20231102
IS  - 1748-880X (Electronic)
IS  - 0007-1285 (Print)
IS  - 0007-1285 (Linking)
VI  - 95
IP  - 1139
DP  - 2022 Oct 1
TI  - Is there any additional benefit of (68)Ga-PSMA PET on radiotherapy target volume 
      definition in patients with glioblastoma?
PG  - 20220049
LID - 10.1259/bjr.20220049 [doi]
LID - 20220049
AB  - OBJECTIVE: To investigate the contribution of (68)Gallium ((68)Ga)-PSMA 
      (prostate-specific membrane antigen) positron emission tomography (PET) in 
      defining radiotherapy (RT) target volume for glioblastoma and to compare the 
      target volumes defined by Magnetic Resonance Imaging (MRI). METHODS: RT planning 
      Computed Tomography (CT) images were fused separately with pre-operative MRI and 
      PET/MRI images of 10 glioblastoma patients, retrospectively. The 
      contrast-enhanced area in T(1) weighted MRI was contoured as gross tumor volume 
      (GTV) and clinical target volume (CTV1) was obtained by including the cavity and 
      T2/FLAIR hyperintense areas after giving a margin of 2 cm to the GTV. (68)Ga-PSMA 
      uptake area was contoured as biological tumor volume (BTV) and CTV2 was obtained 
      with a margin of 2 cm to BTV. Planning target volumes (PTVs) were created with 
      the 3 mm added to the CTVs. Conformity index (CI), dice similarity coefficient 
      (DSC) and overlap volume (OV) were calculated by obtaining the intersection and 
      union volumes. Volumetric comparison, similarity and overlap analyzes were 
      performed statistically by Wilcoxon signed rank and One sample t-test. RESULTS: 
      The median GTV was 21,96 cc (1,04 - 82,04) and BTV was 25,58 cc (2,43 - 99,47). 
      BTV was on average 47% larger than GTV which was statistically significant (p = 
      0.03). For GTV-BTV, CTV1-CTV2 and PTV1-PTV2; mean values of CI were 0,56, 0,76 
      and 0,76; DSC were 0,70, 0,86 and 0,86; OV were 0,88, 0,94 and 0,94, 
      respectively. There was no significant difference on size and spatial similarity 
      between CTV1 and CTV2, PTV1 and PTV2. CONCLUSION: Altough BTV was larger than 
      GTV, this significance was lost while we gave the same CTV margin including the 
      peripheral edema. It seems that it may help to improve defining non-enhancing 
      tumor part and also recurrent tumor volume. ADVANCES IN KNOWLEDGE: Recent studies 
      have focused on the role of (68)Ga-PSMA PET in imaging of glial tumors. It has 
      been observed that (68)Ga-PSMA PET can clearly define the tumor borders and it 
      can be beneficial in target volume delineation, especially in reirradiation of 
      recurrent tumors.
FAU - Sahin, Merve
AU  - Sahin M
AUID- ORCID: 0000-0003-3613-111X
AD  - Department of Radiation Oncology, Istanbul University-Cerrahpasa, Cerrahpasa 
      Faculty of Medicine, Istanbul, Turkey.
FAU - Akgun, Elife
AU  - Akgun E
AD  - Department of Nuclear Medicine, Istanbul University-Cerrahpasa, Cerrahpasa 
      Faculty of Medicine, Istanbul, Turkey.
FAU - Sirolu, Sabri
AU  - Sirolu S
AD  - Department of Radiology, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of 
      Medicine, Istanbul, Turkey.
FAU - Can, Gunay
AU  - Can G
AD  - Department of Public Health, Istanbul University-Cerrahpasa, Cerrahpasa Faculty 
      of Medicine, Istanbul, Turkey.
FAU - Sayman, Haluk Burcak
AU  - Sayman HB
AD  - Department of Nuclear Medicine, Istanbul University-Cerrahpasa, Cerrahpasa 
      Faculty of Medicine, Istanbul, Turkey.
FAU - Oner Dincbas, Fazilet
AU  - Oner Dincbas F
AD  - Department of Radiation Oncology, Istanbul University-Cerrahpasa, Cerrahpasa 
      Faculty of Medicine, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20220920
PL  - England
TA  - Br J Radiol
JT  - The British journal of radiology
JID - 0373125
RN  - 0 (gallium 68 PSMA-11)
RN  - 0 (Gallium Radioisotopes)
RN  - 0 (Radiopharmaceuticals)
SB  - IM
MH  - Humans
MH  - Male
MH  - *Gallium Radioisotopes
MH  - *Glioblastoma/diagnostic imaging/radiotherapy
MH  - Retrospective Studies
MH  - Radiotherapy Planning, Computer-Assisted/methods
MH  - Positron-Emission Tomography
MH  - Tumor Burden
MH  - Magnetic Resonance Imaging/methods
MH  - Radiopharmaceuticals
PMC - PMC9793479
EDAT- 2022/08/23 06:00
MHDA- 2022/10/25 06:00
PMCR- 2023/11/01
CRDT- 2022/08/22 06:43
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2022/10/25 06:00 [medline]
PHST- 2022/08/22 06:43 [entrez]
PHST- 2023/11/01 00:00 [pmc-release]
AID - 10.1259/bjr.20220049 [doi]
PST - ppublish
SO  - Br J Radiol. 2022 Oct 1;95(1139):20220049. doi: 10.1259/bjr.20220049. Epub 2022 
      Sep 20.